Catalyst ligands

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(11) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (25.1 mg) in DMF (150 muL) and DIEA (30 muL), a solution of HBTU (16.7 mg) in DMF (150 muL) was added, then the mixture was added to a solution of compound (Q10) (13.9 mg) in DMF (400 muL) and DIEA (20 muL), and the resulting mixture was stirred at room temperature for 45 minutes. Water (300 muL) was added thereto, and the mixture was purified by preparative HPLC to obtain compound (Q11) (11.1 mg). HPLC (SunFire) rt (min): 10.80 LC/MS (ACQUITY) rt (min): 1.24 MS (ESI, m/z): 1504.6 [M+H]+, 1502.6 [M-H]-, 137076-54-1

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

139-07-1, N-Benzyl-N,N-dimethyldodecan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 6 211.0 g of m-nitrobenzaldehyde dimethylacetal of composition as in Example 4 were reacted according to Example 4. 10.0 g of benzyl-dodecyl-dimethyl-ammonium chloride were used as the emulsifier. After drying, 145.2 g of m-nitrobenzaldehyde were obtained., 139-07-1

As the paragraph descriping shows that 139-07-1 is playing an increasingly important role.

Reference£º
Patent; Bayer Aktiengesellschaft; US4910345; (1990); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

115754-62-6, ((1,3-Dioxolan-2-yl)methyl)tributylphosphonium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,115754-62-6

General procedure: The compounds 4ab were synthesized via modified literature procedure [34]. Aldehyde 3a or 3b (2 mmol) and tributyl(1,3- dioxolan-2-ylmethyl)phosphonium bromide (1.63 g, 4.4 mmol) were dissolved in dry THF (50 mL). Argon was bubbled through the solution for 15 min, NaH (144 mg, 6 mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 100 mL). The combined organic layers were dried (Na2SO4) and the solvents were evaporated in vacuo. The residue was dissolved in THF (100 mL), 12% HCl (50 mL) was added and the solution was stirred for 1 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 100 mL). Both products 4a and 4b are sparingly soluble in common organic solvents. Therefore, the collected organic suspensions was concentrated in vacuo and precipitate was filtered off. The crude product 4a or 4b was suspended in EtOAc (50 mL), the suspension was refluxed for 30 min, cooled to 25 C and the product was isolated by filtration. After drying, products 4a and 4b were used in the following reaction step without further purification. A full purification of small quantities is possible by column chromatography (SiO2, CH2Cl2/EtOAc 10:1) using large excess of the eluting solvents.

115754-62-6 ((1,3-Dioxolan-2-yl)methyl)tributylphosphonium bromide 22292430, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Speratova, Michaela; Jedyrka, Jaroslaw; Pytela, Old?ich; Kityk, Iwan V.; Reshak; Bure?; Klikar; Tetrahedron; vol. 75; 34; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

CORM-349 [Me4N][(OC)3Mn(mu-OCOCH3)3Mn(CO)3]; 150 mg (0.436 mmol) of Mn(CO)5(SO3CF3) and 116 mg (0.872 mmol) of [Me4N][acetate] were stirred in 8 ml of dry THF and 2 ml of methanol, under argon at 50-55 C. for 3 hrs. During this time the colour of the solution went a little darker yellow/orange.Following this, the solvent was removed on rotary evaporator to give a yellow/orange semi-solid residue. This was crystallised from DCM/Ether at -18 C. to give a yellow crystalline product (123 mg, 0.232 mmol). Yield was 100%.Based on the preliminary IR data, the product was initially identified as [Me4N][(Mn(CO)4(OAc)2]. However, additional analysis, particularly X ray crystal structure analysis, has revealed that the product has the title structure. Furthermore, mass spectral data also supports a product having more than one Mn atom.Mr=529.21.1H NMR (CD2Cl2): delta(ppm) 2.29 (s, acetate CH3 6H), 3.33 (s, NMe4 12H)13C NMR (CD2Cl2): delta(ppm) 23.55 (acetate CH3), 56.34 (NMe4), 176.15 (CO), 224.20 (CO)17O NMR (CD2Cl2): delta(ppm) 388.6 (CO)IR (CH2Cl2) nu(cm-1): 2027 (s), 1930 (vs)Mass Spec (ES-) (m/z): 455 ([Mn2(CO)6(OAc)3]-); 315 ([Mn2(CO)(OAc)3]- or [Mn2(CO)4(OAc)(OH)2]-); 257 ([Mn(CO)3(OAc)2]-)Elemental: C16H21Mn2NO12 found (calc) C: 36.80 (36.31), H: 4.90 (4.00), N: 3.60 (2.65)The dimeric structure of the anion has been established by x-ray crystallography.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; Motterlini, Roberto Angelo; Mann, Brian Ernest; Scapens, David Alistair; US2010/105770; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

294-90-6, 1,4,7,10-Tetraazacyclododecane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N-(tert-Butoxycarbonyloxy)succinimide (2.50 g, 11.62 mmol) inchloroform (30 mL) was added dropwise into the solution of1,4,7,10-tetraazacyclododecane (1.00 g, 5.80 mmol) in CHCl3(50 mL) during 7 h. The reaction mixture was stirred 24 h at roomtemperature and the solvent was removed under reduced pressure. The residue was suspended in aqueous NaOH (3 M, 50 mL) and theaqueous phase was extracted with CHCl3 (3 50 mL). The combinedextracts were dried with K2CO3 and evaporated to drynessto give 1,7-bis(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane(10) in quantitative yield.1,3,5-Tris(bromomethyl)benzene (7.65 g, 21.62 mmol) was dissolvedin CHCl3 (150 mL) and Na2CO3 (1.71 g, 16.15 mmol) wasadded. Compound 10 (1.08 g, 2.90 mmol) in CHCl3 (50 mL) wasadded dropwise into the reaction mixture during 11 hours at52 C. The reaction mixture was refluxed for 3 days at 62 C,filtrated, and evaporated to dryness. The residue was purified bysilica gel chromatography (40-70% EtOAc in hexane), giving 11 in27% yield (0.722 g). 1H NMR (500 MHz, CDCl3) d 7.33 (s, 6H), 4.45(s, 8H), 3.71 (s, 4H), 3.21-3.57 (m, 8H), 2.55-2.68 (m, 8H), 1.27(s, 18H). 13C NMR (100 MHz, CDCl3) dppm 155.8, 140.8, 138.5,129.9, 128.3, 79.3, 59.5, 55.2, 46.1, 32.9, 28.4. HRMS(ESI): obsd.921.0840 [M+H]+, Calcd. 921.0795 [M+H]+., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Laine, Maarit; Loennberg, Tuomas; Helkearo, Mia; Loennberg, Harri; Inorganica Chimica Acta; vol. 452; (2016); p. 111 – 117;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

485-71-2, As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: The preparation of the homologous series of osmium complexes with alpha diimineligands was modified from previous literature methods [5]. The precursor Os(L)2Cl2 was synthesized by refluxing ammonium hexachloroosmate in a 1:2 M ratio with L = 2,2?-bipyridine (bpy), 1,10-phenanthroline (phen), or bathophenanthroline (dpp) in 10 mL of ethylene glycol under nitrogen for 45 min. After cooling to room temperature, sodiumhydrosulfite (0.17 M) was added to reduce the osmium from Os(IV) to Os(II). Precipitation of Os(bpy)2Cl2,Os(phen)2Cl2, and Os(dpp)2Cl2 was achieved via an ice-bath,and the solid was washed with deionized water and ethylether. Yields were close to 80 %.

1662-01-7, The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wagner, Amy M.; Strohecker, Sarah A.; Costello, Elizabeth K.; Rood, Jeffrey A.; Kneas, Kristi A.; Journal of Fluorescence; vol. 26; 6; (2016); p. 2271 – 2280;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

554-95-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.554-95-0,Benzene-1,3,5-tricarboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: Reaction of AgNO3 (33.4 mg, 0.2 mmol), pyridazine (pdz) (16.0 mg, 0.2 mmol) and 1,3,5-benzene tricarboxylic (H3btc) (44.2 mg, 0.2 mmol) took place in H2O-DMF (N,N-Dimethylformamide) solvents (6 ml, v/v = 1:1) in the presence of ammonia (0.5 mL, 14 M) under ultrasonic treatment (160 W, 40 kHz,30 min) at 40 C. The resultant colourless solution was allowed slowly to evaporate at room temperature in the dark. The yellow crystals of complex 1 were obtained after several days.The crystals were isolated by filtration and washed by deionized water and ethanol and dried in the air. Yield based on Ag is 88% .Elemental analysis: Anal. Calc. for Ag6C26H14N4O12: C, 25.563; H,1.155; N, 4.586. Found: C, 25.37; H, 1.19; N, 4.65%. Selected IR peaks (cm1): 3283 (s), 2264 (w), 1863 (w), 1614 (s), 1557 (s),1417 (s), 1360 (s), 1099 (m), 1060 (w), 972 (w), 920 (w), 767 (s), 716 (s), 660 (w), 514 (m), 455 (w).

As the paragraph descriping shows that 554-95-0 is playing an increasingly important role.

Reference£º
Article; Wang, Dan-Feng; Zhang, Ting; Dai, Si-Min; Huang, Rong-Bin; Zheng, Lan-Sun; Inorganica Chimica Acta; vol. 423; PART A; (2014); p. 193 – 200;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI